MRI Interpretation, Hemorrhage, and Multidisciplinary Monitoring in PLGG

In this segment, Dr. Abdelbaki, Dr. Chi, Dr. Chintagumpala, and Dr. Margol discuss how to interpret MRI changes and clinical findings in the context of a slow-growing pediatric low-grade glioma (PLGG), and the role of multidisciplinary care.

Tumor size at diagnosis, whether 1 cm or 5 cm, typically does not change management, which depends on location and biology, and a delayed diagnosis should not be a source of parental guilt given the slow-growing nature of these tumors. With 80%–85% overall survival, "time is on our side." Small millimeter changes between consecutive scans can be misleading; imaging should be compared to a baseline MRI, typically the scan after the last intervention, rather than only the most recent study. A 2-millimeter change over 18 months is far less concerning than it may appear on a single report.

Intratumoral hemorrhage, distinct from intracystic hemorrhage, is rare but can occur, particularly in older children who have undergone multiple treatments, and may be detected incidentally on routine MRI. Clinical significance depends on tumor location, with hemorrhage near the optic pathway carrying greater consequence than in a hemispheric location. Importantly, sudden vision loss can occur without detectable tumor growth, likely from undetectable progression destroying remaining optic nerve fibers, reinforcing that patient symptoms do not always match the imaging picture. Multidisciplinary care—ophthalmology, endocrinology, neurology, rehabilitation medicine, and neurosurgery—is essential to monitor functional outcomes beyond MRI measurements alone.

In the next episode, "Treatment Sequencing and Regimen Selection in PLGG," the panel discusses how to strategically sequence therapies and select regimens across the chronic course of PLGG while balancing practical considerations for families.